Baxter International Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andrew Hider
- Full Time Employees
- 37,500
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- One Baxter Parkway Deerfield IL United States of America 60015
- IPO Date
- Oct 27, 1981
- CIK
- 0000010456
- Website
- baxter.com
- Similar Companies
- Business
- Baxter International Inc specializes in medical products and therapies, healthcare system technologies, and pharmaceuticals. The company's main products include advanced surgical technologies under its Advanced Surgery division, infusion therapies and intravenous delivery systems under Infusion Therapies and Technologies, and hospital pharmaceuticals focusing on pain management, critical care, anti-infection, and oncology. Its Healthcare Systems and Technologies segment operates through divisions such as Front Line Care, Digital Platform and Innovations, Care and Connectivity Solutions, and Global Services. Baxter serves healthcare providers globally, offering products used at the hospital bedside, operating rooms, intensive care units, home care, and alternate care settings. Founded in 1931 and headquartered in Deerfield, Illinois, Baxter operates worldwide and emphasizes innovation to improve patient outcomes and operational efficiency. Recently, Baxter has undergone significant strategic transformations including the spin-off of its Renal Care and Acute Therapies global business units to establish a separate publicly traded company, streamlining its commercial and manufacturing footprint to enhance business performance, and reviewing strategic alternatives for its BioPharma Solutions business. In 2025, the company appointed Andrew Hider as CEO to advance continuous improvement and sustainable growth. Baxter launched the Welch Allyn Connex 360 Vital Signs Monitor, a next-generation connected patient monitoring device, and achieved recognition with a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative in categories including IV Solutions, Nutrition Solutions, and Premix Drugs. The company also completed the integration of its Hill-Rom acquisition and continues to focus on operational simplification by reducing distribution centers and enhancing digital health solutions. Baxter reported third-quarter 2025 sales growth driven by Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals segments with ongoing investments in R&D to support steady product launches and innovation.
Company News
Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
Are Investors Undervaluing Baxter International (BAX) Right Now?
Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?
Baxter Releases Inaugural Connected Hospital Report
Baxter International Inc. (NYSE:BAX) Stock Now Rated “Hold” by Wall Street Analysts
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
Bank of America Corp DE Makes New Investment in Baxter International Inc. $BAX
Baxter International Inc. $BAX Shares Bought by NewEdge Advisors LLC
TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis
Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Richard Pzena Buys Globant SA (GLOB) -- Shares Look 78% Undervalued on GF Value
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Barbara Oil Co. Makes New $853,000 Investment in Baxter International Inc. $BAX
Baxter Appoints John Rogers Chief Financial Officer
Baxter Announces Pricing for Its Upsized Cash Tender Offers
Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers
A Look at Baxter International Inc (BAX) After 3.1% Decline -- GF Value $33.00 vs Price $25.91
Richard Pzena Buys LKQ Corp (LKQ) -- Shares Look 38% Undervalued on GF Value
Baxter Announces Cash Tender Offers